FEMASYS INC (FEMY): Price and Financial Metrics
GET POWR RATINGS... FREE!
FEMY Stock Summary
- FEMASYS INC's market capitalization of $14,530,740 is ahead of only 6.11% of US-listed equities.
- With a one year PEG ratio of 0.42, FEMASYS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.99% of US stocks.
- FEMY's went public 1.78 years ago, making it older than only 4.98% of listed US stocks we're tracking.
- Stocks that are quantitatively similar to FEMY, based on their financial statements, market capitalization, and price volatility, are PSTV, GILT, PALT, TAOP, and KOPN.
- To dig deeper into the stock's financial statements, go to FEMY's page on browse-edgar?action=getcompany&CIK=0001339005.
FEMY Valuation Summary
- In comparison to the median Healthcare stock, FEMY's price/sales ratio is 151.06% higher, now standing at 11.8.
- FEMY's EV/EBIT ratio has moved up 21.7 over the prior 21 months.
Below are key valuation metrics over time for FEMY.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| FEMY | 2023-03-24 | 11.8 | 0.8 | -1.3 | 0.1 |
| FEMY | 2023-03-23 | 11.6 | 0.8 | -1.3 | 0.1 |
| FEMY | 2023-03-22 | 11.3 | 0.8 | -1.3 | 0.1 |
| FEMY | 2023-03-21 | 11.1 | 0.8 | -1.3 | 0.1 |
| FEMY | 2023-03-20 | 11.1 | 0.8 | -1.3 | 0.1 |
| FEMY | 2023-03-17 | 10.8 | 0.7 | -1.2 | 0.2 |
FEMY Price Target
For more insight on analysts targets of FEMY, see our FEMY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $21.50 | Average Broker Recommendation | 1.5 (Moderate Buy) |
FEMY Stock Price Chart Interactive Chart >
FEMY Price/Volume Stats
| Current price | $1.08 | 52-week high | $2.97 |
| Prev. close | $1.15 | 52-week low | $0.57 |
| Day low | $1.04 | Volume | 3,792 |
| Day high | $1.10 | Avg. volume | 15,404 |
| 50-day MA | $1.16 | Dividend yield | N/A |
| 200-day MA | $1.43 | Market Cap | 12.70M |
FEMASYS INC (FEMY) Company Bio
Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Latest FEMY News From Around the Web
Below are the latest news stories about FEMASYS INC that investors may wish to consider to help them evaluate FEMY as an investment opportunity.
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device-- FemCath™ is the first FDA-cleared intrauterine catheter that allows for selective evaluation of a fallopian tube with contrast -- -- FemCath is used in conjunction with FemVue as a baseline diagnostic test for infertility -- ATLANTA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced |
Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons--FemCerv®, the first endocervical tissue sampler of its kind in the detection of cervical cancer, was well-received after being presented at the AAGL conference attended by over 2,000 leading gynecologic specialists-- ATLANTA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today reported that it h |
Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design--FemaSeed de novo trial enrollment has accelerated with trial recruitment focus on male factor infertility--ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that it has completed over 25% of its targeted enrollment (214 patient fertility cycles) in its FemaSeed® de novo tria |
Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare ConferenceATLANTA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Kathy Lee-Sepsick, founder, president & chief executive officer, will present at the Piper Sandler 34th Annual Healthcare Conference being held November 29 through December 1, 2022 at the Lotte New York Palace Hotel in |
Analysts’ Top Technology Picks: AppLovin (APP), Femasys (FEMY)There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on AppLovin (APP – Research Report) and Femasys (FEMY – Research Report) with bullish sentiments. AppLovin (APP) Goldman Sachs analyst Eric Sheridan maintained a Buy rating on AppLovin on November 10 and set a price target of $33.00. The company's shares closed last Friday at $16.94, close to its 52-week low of $13.20. According to TipRanks. |
FEMY Price Returns
| 1-mo | 0.93% |
| 3-mo | 20.00% |
| 6-mo | -4.42% |
| 1-year | -52.21% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 20.00% |
| 2022 | -76.92% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...